

Table 25. TUDD analysis

QLQ-C30 or BR23 Dimension	ARM	Number of events	Median TUDD (95%CI)	HR _{B/A} (95% CI)	p-value
Global health state	A	16/26 (62%)	4.6 months (2.5-.)	1	0.68
	B	11/25 (44%)	6.5 months (2.3-.)	0.85 (0.39-1.84)	
Physical functioning	A	16/26 (62%)	6.4 months (2.3-.)	1	0.33
	B	10/25 (40%)	6.7 months (2.6-.)	0.67 (0.30-1.49)	
Role functioning	A	18/26 (69%)	6.3 months (2.6-14)	1	0.88
	B	13/25 (52%)	4.2 months (2.3-11.2)	0.95 (0.46-1.94)	
Emotional functioning	A	13/26 (50%)	15.6 months (8.4-.)	1	0.29
	B	12/25 (48%)	6.6 months (2.3-.)	1.54 (0.70-3.39)	
Cognitive functioning	A	13/26 (50%)	15.6 months (3.3-.)	1	0.55
	B	12/25 (48%)	6 months (2.6-.)	1.27 (0.57-2.83)	
Social functioning	A	16/26 (62%)	6.4 months (3.3-.)	1	0.34
	B	14/25 (56%)	4.2 months (2.4-6.7)	1.42 (0.69-2.93)	
Body image	A	12/26 (46%)	13.4 months (4.4-.)	1	0.13
	B	12/25 (48%)	4.2 months (2.4-8.3)	1.85 (0.83-4.15)	
Sexual functioning	A	9/26 (35%)	14 months (4.5-.)	1	0.70
	B	8/25 (32%)	6.6 months (2.3-.)	1.21 (0.47-3.14)	
Future perspective	A	7/26 (27%)	33.8 months (13.4-.)	1	0.27
	B	8/25 (32%)	9.4 months (2.4-.)	1.79 (0.64-5.02)	
Fatigue	A	17/26 (65%)	6.4 months (3.1-15.6)	1	0.20
	B	15/25 (60%)	2.4 months (2.3-4.4)	1.59 (0.79-3.22)	
Nausea-vomiting	A	15/26 (58%)	6.5 months (2.5-.)	1	0.50
	B	10/25 (40%)	8.3 months (2.5-.)	0.76 (0.34-1.69)	
Pain	A	16/26 (62%)	6.6 months (4.4-.)	1	0.63
	B	11/25 (44%)	6.7 months (4.2-.)	0.83 (0.39-1.54)	
Dyspnoea	A	14/26 (54%)	15.6 months (6.4-.)	1	0.12
	B	14/25 (56%)	5.2 months (2.6-8.3)	1.81 (0.85-3.85)	
Insomnia	A	9/26 (35%)	22.3 months (13.4-.)	1	0.002
	B	13/25 (52%)	2.6 months (2.3-8.3)	4.06 (1.70-9.71)	
Appetite loss	A	13/26 (50%)	22.3 months (2.7-.)	1	0.39
	B	8/25 (32%)	. months (2.6-.)	0.67 (0.28-1.64)	
Constipation	A	10/26 (38%)	33.8 months (13.4-.)	1	0.95
	B	8/25 (32%)	. months (6-.)	1.03 (0.40-2.64)	
Diarrhoea	A	17/26 (65%)	2.7 months (2.3-13.4)	1	0.056
	B	10/25 (40%)	9.4 months (6.2-.)	0.46 (0.21-1.02)	
Financial difficulties	A	13/26 (50%)	14 months (8.6-.)	1	0.26
	B	7/25 (28%)	. months (8.3-.)	0.59 (0.23-1.49)	
Systemic therapy side effects	A	16/26 (62%)	2.5 months (2.2-13.4)	1	0.64
	B	15/25 (60%)	2.5 months (2.2-4.4)	1.19 (0.58-2.41)	
Breast symptoms	A	9/26 (35%)	22.3 months (10.3-.)	1	0.82
	B	7/25 (28%)	. months (4.4-.)	0.89 (0.33-2.44)	
Arm symptoms	A	10/26 (38%)	14 months (4.4-.)	1	0.95
	B	8/25 (32%)	. months (2.4-.)	0.97 (0.38-2.48)	